Company Description
QuidelOrtho Corporation provides diagnostic testing solutions.
The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units.
The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases.
The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings.
The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics.
The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use.
It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 1979 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 7,100 |
| CEO | Michael S. Iskra |
Contact Details
Address: 9975 Summers Ridge Road San Diego, California 92121 United States | |
| Phone | (858) 552-1100 |
| Website | quidelortho.com |
Stock Details
| Ticker Symbol | QDEL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001906324 |
| CUSIP Number | 219798105 |
| ISIN Number | US2197981051 |
| Employer ID | 87-4496285 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Michael S. Iskra | Interim Chief Executive Officer, Executive Vice President and Chief Commercial Officer |
| Robert J. Bujarski J.D. | Interim President, Executive Vice President and Chief Operating Officer |
| Joseph M. Busky CPA | Chief Financial Officer |
| Dr. Werner Kroll Ph.D. | Senior Vice President of Research and Development |
| Louise M. Brandy | Chief Information Officer |
| Ruben Argueta | Director of Investor Relations |
| Michelle A. Hodges J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| William J. Ferenczy | Point of Care Business Unit Leader |
| Tamara A. Ranalli | Molecular Diagnostics Business Unit Leader |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2024 | ARS | Filing |
| Apr 2, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 2, 2024 | DEF 14A | Other definitive proxy statements |
| Feb 29, 2024 | 8-K/A | [Amend] Current report |
| Feb 29, 2024 | 10-K | Annual Report |
| Feb 21, 2024 | 8-K | Current Report |
| Feb 16, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | 8-K | Current Report |